You are here

  • Home
  • Archive
  • Volume 76, Issue 12
  • Response to: ‘The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis’ by Pirilä et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis’ by Pirilä et al
  1. Josef S Smolen1,
  2. Robert B M Landewé2,
  3. Désirée van der Heijde3,4
  1. 1Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna, Austria
  2. 2Rheumatology, Atrium Medical Center Heerlen, Heerlen, The Netherlands
  3. 3Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  4. 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  1. Correspondence to Professor Josef S Smolen, Division of Rheumatology, Department of Medicine, Medical University of Vienna, Vienna 1090, Austria; josef.smolen{at}wienkav.at

https://doi.org/10.1136/annrheumdis-2017-211524

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The views presented by Pirilä et al,1 which focus primarily on the FINnish Rheumatoid Arthritis Combination therapy (FIN-RACo) trial, have been taken into serious consideration by the task force. Indeed, as extensively explained in the text accompanying the updated European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations,2 several committee members referred to the references provided by Pirilä et al as well as other publications on this topic. The discussion also included comments that in some countries local societies recommended combination therapy with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) (csDMARDs), and this is also mentioned in the publication. Nevertheless, after a long debate regarding csDMARD combinations, the task force arrived at …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles